



Diabetes mellitus is a non-communicable disease with a high 
prevalence today affecting about 429 million adults globally 
and is expected to rise by 147% to 629 million in 2045.[1] 
According to the American Diabetes Association, diabetes 
can be diagnosed using plasma glucose concentrations above 
acceptable cut‑offs in the presence of symptoms suggestive of 
hyperglycemia. Fasting plasma glucose ≥7.0 mmol/L (126 mg/
dl) and 2 h plasma glucose level ≥11.1 mmol/L (200 mg/dL) 
following a 75 g glucose drink dissolved in 250 mL to 300 mL 
of water are considered to be in the diabetic range.[2] Duration 
of fasting is expected to last for at least 8–10 h overnight and 
the test is conducted at dawn.
Diabetes mellitus can also be diagnosed using glycated 
hemoglobin (HBA1c). HBA1c is formed when glucose 
combines nonenzymatically with the N-terminal valine 
residue of each beta chain of hemoglobin A. The formation 
of HbA1c is irreversible and the blood concentration relies 
on both the half-life of the erythrocytes and the level of blood 
glucose. HbA1c has been approved for the diagnosis of both 
prediabetes (≥5.7%) and diabetes (≥6.5%).[3]
Effective management of diabetes mellitus requires the periodic 
measurement of both fasting plasma glucose and HbA1c. The 
practice of using self-monitoring blood glucose (SMBG) 
Introduction/Background: Diabetes mellitus is highly prevalent in both developed and developing countries today affecting about 429 
million adults globally and is expected to rise by 147% to 629 million in 2045. Effective management of diabetes mellitus requires the 
periodic measurement of fasting plasma glucose. Self-monitoring blood glucose has been used to achieve this for over three decades 
now. This study, therefore, assesses the performance of three blood glucose meters used by patients with diabetes in our environment. 
Materials and Methods: This study adopted a comparative analytical prospective design that involved three of the frequently used glucose 
meters in our environment namely RUBY®, ONCALL®, and FINETEST®. Glucose calibrators of increasing concentrations from 40 mg/dL to 
200 mg/dL were prepared from a freshly constituted 1800 mg/dl stock solution of glucose. Sera obtained from five patients were assayed along 
with control sera using a routine laboratory method (glucose oxidase [GOX]) for standardization and the three glucose meters simultaneously 
and the results were compared for statistical differences on Microsoft Excel using means and standard deviation. P ≤ 0.05 was set as a level 
of significance. Results: The mean glucose values of calibrators (120 ± 63.3) were statistically significantly different from the mean glucose 
values of the RUBY (139.6 ± 80.9), (P = 0.0118) and the ONCALL (188.8 ± 82.1), (P ≤ 0.0001) glucose meters, respectively. The percentage 
increase in blood glucose estimation by the RUBY and ONCALL devices was 115.8% and 157.3% respectively. The FINETEST glucose 
meter overestimated glucose by 232.0% higher than the laboratory GOX method even though there was no statistical significance (P = 0.062) 
between the two means. The percentage imprecision for the different glucose meters was: RUBY 9.5%, FINETEST 14.8%, and ONCALL 
18.2%. Conclusion: Quality control should be used routinely in the use of point of care testing glucose measurements and devices should be 
sent to the central laboratory periodically for recalibration to avoid mismanagement of diabetic patients on hypoglycaemic drugs.
Keywords: Diabetes mellitus, point of care testing, self-monitoring of blood glucose
Address for correspondence: Dr. Eyam Sunday Eyam, 
Department of Chemical Pathology, University of Calabar, Calabar, Nigeria. 
E‑mail: dr.eyam@yahoo.com
This is an open access journal, and articles are distributed under the terms of the Creative 
Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to 
remix, tweak, and build upon the work non‑commercially, as long as appropriate credit 
is given and the new creations are licensed under the identical terms.
For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com
How to cite this article: Inaku KO, Eyam ES, Emin EJ, Onuche OL. 
Self-monitoring of blood glucose can be misleading without periodic 
re-calibration of glucose meters: A pilot study. Niger J Med 2021;30:259-63.
Submitted: 17-Dec-2020 Revised: 29-Jan-2021
 Accepted: 12-Apr-2021 Published: 19-Jun-2021
Self-monitoring of Blood Glucose can be Misleading without 
Periodic Re-calibration of Glucose Meters: A Pilot Study
Kenneth Ogar Inaku1, Eyam Sunday Eyam1, Emin Johnson Emin2, Onuche Lawrence Onuche2
1Department of Chemical Pathology, University of Calabar, Calabar, 2Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria






© 2021 Nigerian Journal of Medicine | Published by Wolters Kluwer - Medknow 259
Inaku, et al.: Self‑monitoring of blood glucose can be misleading without periodic re‑calibration of glucose meters: A pilot study
alongside glucose meters has been around for over three 
decades now.[4] It allows patients to perform glucose testing by 
themselves or their relatives and Keep records of their blood 
glucose readings. The aim is to achieve early blood glucose 
control which has numerous benefits such as delay in onset of 
hyperglycemic complications[5] and reduction in the frequency 
of hospital visits. SMBG also allow patients to get involved 
in the management of their condition and allow the incidence 
of hypoglycemia while attempting to achieve tight glycemic 
control. To achieve these benefits, the results obtained from 
glucose meters should be representative of the true glycemic 
states of the patients. However, this may not always be true due 
to some factors. One such factor is the stability and reliability 
of the blood glucose measuring instrument used. Point of care 
testing (POCT) devices can malfunction leading to falsely high 
or low results with the consequence of mismanagement of 
the patient’s condition.[6] This study, therefore, compared the 
performances of three blood glucose meters used by diabetes 




The study was carried out in the Department of Chemical 
Pathology of the University of Calabar Teaching 
Hospital (UCTH), Calabar. UCTH is a tertiary hospital 
located in the South-South geopolitical zone of Nigeria with 
over 600‑bed spaces in various clinical departments staffed 
with specialists. It serves as a referral center to other primary 
and secondary health facilities in Cross River State and 
neighboring Akwa Ibom State.
Study design
It was a comparative analytical study that involved the 
calibration of different glucose meters to verify their accuracy, 
linearity, and reproducibility of results. We used three of the 
frequently used glucose meters by patients in our environment 
namely Medismart® RUBY blood glucose monitoring 
system-Lobeck Medical AG, (Schulstrasse 19 CH-5070 
Frick/Switzerland), ONCALL® by ACON Diabetes Care, 
Califonia-USA, and Finetest® by Infopia Co. Ltd., Kyunggi, 
431‑080, Korea. Five different calibrators of glucose with 
increasing concentrations from 40 mg/dL to 200 mg/dL were 
prepared from a freshly constituted 180 mg/dl glucose stock 
solution. Two of the devices (RUBY® and ONCALL®) were 
used to measure the predetermined concentrations of the 
calibrators. A spectrophotometer (Spectro SC by Labomed 
Inc. Los Angeles, CA 90034 U.S.A.) in routine use in the 
laboratory was used to determine the absorbance of the 
different concentrations, and a graph of absorbance against 
concentration was used to determine the concentration of 
the control serum. The obtained value of the control serum 
was compared with expected. The mean and standard 
deviation (SD) of the concentrations of the different calibrators 
from the glucose meters were then calculated and compared 
with the concentrations of the calibrators. Different plasma 
samples sent to the laboratory for routine analyses were tested 
using the third glucose meter (FINETEST®). The results 
obtained were compared with the routine laboratory GOX 
method. A control serum was used to determine the coefficient 
of variation (CV) of each glucose meter. The sample was 
assayed using 10 glucometer strips on the three glucose meters. 
The mean and SDs were determined. The CV was calculated 
from the formula, CV = SD/mean × 100% and the results were 
expressed as a percentage.
Statistical analysis
Results obtained were analyzed using Microsoft Excel and 
Graphpad software. The mean of the different results was 
compared for significance using Paired‑samples t-test at the 
alpha level of P ≤ 0.05.
results
A summary of some of the characteristics of the three glucose 
meters used in this study is shown in Table 1. The most a 
method used is the enzyme method including GOX and 
glucose-1-dehydrogenase (GDH). Table 2 is a representation 
of results obtained from two of the three glucose meters 
namely: RUBY and ONCALL. Statistically significant 
differences were observed between the mean values of 
glucose calibrator measurements of RUBY (P = 0.0118) 
and ONCALL (P < 0.0001) glucose meters. The percentage 
increase in glucose calibrators’ estimation by the RUBY and 
ONCALL was 115.8% and 157.3% respectively. Figure 1 is a 
graphical representation of the different glucose readings by 
the glucose meters (RUBY and ONCALL) in relation to the 
calibrators. Both glucose monitoring devices appear to deviate 
more with increasing glucose concentration.
Table 3 is a comparison of glucose measurements from the 
FINETEST® glucose meter with our routine laboratory GOX 
method. The FINETEST glucose meter overestimated glucose 
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Table 1: Summary of point of care glucose meters used in the study
Company and Device Method Analytical Range (mg/dl)
Enzyme Analysis
MediSmart® RUBY, Switzerland FAD –GDH Amperometric technique 20-630
ACON ON-CALL® Plus II, California, USA GOX Amperometric technique 20-600
INFOPIA Finetest® Auto Coding, Kyunggi, Korea - Amperometric technique 10-600
FAD-GDH Flavin adenine dinucleotide-glucose dehydrogenase; GOX-Glucose oxidase
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by 232.0% higher than the routine laboratory GOX method 
although the difference between the two means was not 
statistically significant (P = 0.062). The reference interval for 
the control solution was 3.2–5.1 mmol/L. The calculated CV 
for the respective glucose meters was 9.5% for RUBY, 15.8% 
for FINETEST, and 18.2% for ONCALL.
dIscussIon
This pilot study has shown that results from some POCT 
devices used for SMBG can be significantly different from 
the true value and if applied to patient management may result 
in adverse consequences. Faulty glucose meters can either 
overestimate or underestimate blood glucose depending on 
the sources of error. Errors can come from poor storage of 
the device, suboptimal battery life, malfunctioning sensor, or 
improper storage of test strips such as exposure to atmospheric 
air for longer than necessary, and many more.[7] Some glucose 
meters also require the replacement of codes for each new 
batch of test strips and when this is not followed can result 
in unreliable results. The RUBY® glucose meter in this study 
on average overestimated the calibrators by up to 116.3% 
of the expected value while the ONCALL®overestimated 
the expected value by 157.3%. This is a course for worry. 
Putting it in perspective, the implication is that a patient with 
a fasting plasma glucose value of 90 mg/dl (5.0 mmol/L) by 
routine laboratory method will have a reading of 104.7 mg/
dl (5.8 mmol/l) and 141.6 mg/dl (7.8 mmol/l) from the RUBY® 
and ONCALL® glucose meters, respectively. Since the aim 
of testing is to monitor glycemic control, it can be said that 
applying such results in patient management will have adverse 
consequences in the long run. The effect of such false results 
was brought to the limelight in the case of a 45-year-old 
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man on warfarin therapy, digitalis, and beta-blockers for 
tricuspid valve replacement. He developed thrombosis as a 
complication despite 12 consecutive normal international 
normalized ratios results from his POCT device. A comparison 
with laboratory-generated results revealed that he was getting 
inadequate anticoagulation therapy leading to thrombosis. His 
therapy was adjusted in line with the new laboratory-generated 
results.[6] This example emphasizes the need for periodic 
re-calibration of POCT devices.
There are minimum required standards that must be met by 
POCT glucose meters as set out by International Organization 
for Standardization 15179: 2003.[8] These guidelines require 
that 95% of each glucose level are in the range of ± 15 mg/
dl ≤75 mg/dl, ±20% >75 mg/dl when compared to the reference 
measurements.[8] Ten years later in 2013, these requirements 
were revised.[9] The new requirements are that at blood 
glucose <75 mg/dl, 99% of values should be ± 15 mg/dl; while 
at >75 mg/dl glucose concentration, 99% of measurements 
should be ± 15% of reference measurements.[9] According to 
the National Committee for Clinical Laboratory Standards the 
allowable analytical error should be <5% and total error (bias 
and imprecision including manipulation) should be <7.9%.[10] 
None of the glucose meters used in this study met these 
requirements. Meeting these targets of accuracy by POCT 
devices is a crucial factor to guide monitoring and adjustment 
of therapy. However, upholding test precision and performance 
are the major challenges in POCT. These challenges are 
compounded by the increasing number of different operators 
and instrument brands available.[7,11] To address the issue of 
test performance, three factors were identified as critical. 
According to a recent publication by the American Association 
Figure 1: Graph showing the comparison of concentration of the 
calibrators and the results of the different glucose meters tested. T1–T5 
are the different calibrators used in the experiment with the following 
concentrations: T1 = 40 mg/dl, T2 = 80 mg/dl, T2 = 120 mg/dl, 
T4 = 160 mg/dl and T5 = 200 mg/dl
Table 2- Comparison of calibrator measurements of RUBY® and ONCALL® Glucose meters using paired student’s t-test
Variable/Test T1 T2 T3 T4 T5 Mean±SD Difference (%) P
STANDARD (mg/dL) 40 80 120 160 200 120±63.25 - -
RUBY® READINGS (mg/dl) 30 91 124 195 258 139.60±89.3 19.6 (115.8) 0.0118*
ONCALL READINGS (mg/dL) 62 159 207 252 264 188.80±82.1 68.8 (157.3) <0.0001*
*P<0.05 is considered significant














6 (control) 3.7 6.2
Mean±SD 5.4±2.6 12.5±9.9 0.062
The reference for the control solution was 3.2-5.1mmol/L. P ≤0.05 was 
considered significant.
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of Clinical Chemistry (AACC) Academy, the user must 
understand (i) the operation of the POCT device, (ii) how to 
troubleshoot system errors, (iii) the essence of using quality 
control (QC) materials (iv) how to handle and store of QC 
materials.[12] These are lacking in our health care setting as was 
observed in a previous survey carried out in our hospital.[13]
The principles used by the glucose-monitoring POCT devices 
can also be a source of error. Most devices employ the use of 
enzymes, commonly GOX and GDH as was the case with 
ONCALL and RUBY glucose meters used in this study, 
respectively. In the GOX method, the enzyme catalyzes the 
oxidation of glucose to gluconic acid and hydrogen peroxide. 
This first step is very specific to glucose and the observed 
level of hydrogen peroxide is related to the level of glucose 
in the sample. The difference in the concentration of hydrogen 
peroxide is monitored photometrically with a chromogen that 
will produce a color change or amperometrically by measuring 
the amount of electric current generated. The second step 
which involves a peroxidase is not as precise as the reaction 
of GOX. This is because elements such as uric acid, ascorbic 
acid, bilirubin, tetracycline, and glutathione inhibit the reaction 
with attendant drop in glucose level.[14]
The GDH enzyme catalyzes the oxidation of glucose to 
gluconolactone. In older glucose measuring instruments, 
a coenzyme is used to reduce nicotinamide adenine 
dinucleotide (NAD) to NADH. The level of NADH can be 
measured photometrically or amperometrically – as used in all 
devices in this study and is proportional to the blood glucose 
concentration. Newer devices make use of the coenzyme 
pyrrolo-quinolinequinone (PQQ) which is less sensitive to 
ambient oxygen and electrochemical interference. Although 
the method produces results in close agreement with the 
reference hexokinase method, products containing maltose 
or galactose spuriously increase results obtained with POCT 
that use GDH-PQQ. Both methods have been adapted on 
autoanalyzers for use in central chemistry laboratories with 
various modifications to reduce interference and improve the 
accuracy of results.[14,15] Results from this study will go to 
suggest that the GDH method is more accurate than the GOX 
method since the RUBY meter has the smallest percentage 
imprecision.
Operator education and training are key factors that have been 
identified to improve test performance.[16,17] These have a direct 
bearing on user competency. Most operators of POCT devices 
in our hospitals learned how to operate the device from friends, 
health care workers, instrument vendors or product leaflet 
among others.[13] Granted, the operation of POCT glucose 
meters are classified as waived testing under the CLIA ’88 
and as such require minimal training to operate,[18] and newer 
models are designed with technological advances that decrease 
operator errors,[19] however, there are evidence that user 
competency can affect the quality of results. A study by Huang 
et al.[20] assessed the effect of user proficiency on the rational 
operation of glucose meters. The number of QCs performed by 
each operator was used as an indication of competency and the 
degree of inaccuracy of the measurements indicating the level 
of analytical performance. After analyzing up to 59,000 QC 
points from 20 different glucose meters, they found that users 
who performed fewer QC tests were more likely to generate 
results with greater imprecision.[20]
Although understanding the use of QC materials was 
identified as a crucial factor in the assessment of the analytical 
performance of POCT devices,[12] this practice is not common 
among our POCT device operators, neither in the hospital 
setting[13] nor among diabetics who practice SMBG. In one 
recent survey, only about a quarter of respondents admitted 
to using QC materials on their POCT devices.[13] One possible 
reason for this low practice may be due to a lack of knowledge 
of the benefits associated with the use of control materials 
routinely. This can be addressed by the education of POCT 
operators and the availability of POCT QC materials by the 
central laboratory. As shown by Huang et al.,[20] periodic 
QC can be used to access the percentage imprecision of an 
instrument over a long period. All these will be possible if each 
hospital sets up a QC Monitoring Committee as recommended 
by the AACC Academy.[12]
There are some limitations to this study. It was not feasible for 
us to estimate the percentage imprecision of the glucose meters 
over a long period due to the lack of regular QC practices 
by the operators. Another limitation was the low number 
of calibrators tested. Testing at least 20 calibrators and sera 
by the glucose meters and laboratory methods would have 
strengthened our conclusions reached. However, despite these 
limitations, this pilot study has highlighted the importance of 
periodic calibration of glucose meters and the potential benefit 
of regular use of QC materials while testing.
conclusIon
There is a need to introduce QC into POCT in our hospitals. 
This can be facilitated by encouraging management to 
constitute a POCT committee and educating operators of 
such devices to submit the same for routine quality checks. 
The different QC values from the various POCT devices can 
be periodically analyzed to ascertain their performances. This 
will improve the quality of results generated from point of 
care glucose meters and the overall management of diabetes 
patients using SMBG in our environment.
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